Shoichi Hazama

This inventor holds 11 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Cytlimic Inc., Toyo Kohan Co., Ltd., Yamaguchi University. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shoichi Hazama. Retrieved from https://idiyas.com/inventor/shoichi-hazama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 1(Granted Patents)

Location History:

Ube, JP (2019 - 2023)
Yamaguchi, JP (2020 - 2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2025-10-21),

2. 11692216 - Method for assisting prediction of risk of occurrence of side effect of irinotecan (2023-07-04),

3. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same (2023-04-04),

4. 11384385 - Method for predicting therapeutic effects of irinotecan, and kit for same (2022-07-12),

5. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

6. 11111526 - Buffer composition for hybridization and hybridization method (2021-09-07),

7. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

8. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-03-17),

9. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2020-01-21),

10. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells (2020-01-07),

11. 10450601 - Buffer composition for hybridization use, and hybridization method (2019-10-22),

Title: Shoichi Hazama: Innovator in Pharmaceutical Technology

Introduction

Shoichi Hazama is a prominent inventor based in Yamaguchi, Japan. He has made significant contributions to the field of pharmaceutical technology, particularly in the prediction of side effects related to cancer treatments. With a total of 10 patents to his name, Hazama's work has the potential to impact patient care and treatment outcomes.

Latest Patents

One of Hazama's latest patents is a method for assisting in the prediction of the risk of occurrence of side effects of irinotecan. This invention aims to provide a simple and efficient device for predicting such risks by analyzing single nucleotide polymorphisms in specific genes. The genes involved include APCDD1L, R3HCC1, OR51I2, MKKS, EDEM3, and ACOX1. By determining the genetic makeup of a test subject, the device can assess whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.

Another notable patent involves a MUC1-derived peptide and a pharmaceutical composition for the treatment or prevention of cancer. This invention provides a peptide that consists of eight or more consecutive amino acid residues from a specified sequence and is designed to enhance immune responses.

Career Highlights

Throughout his career, Shoichi Hazama has worked with various companies, including Cytlimic Inc. and Toyo Kohan Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.

Collaborations

Hazama has collaborated with notable individuals in his field, including Masaaki Oka and Tomoya Miyakawa. These partnerships have likely facilitated the development of his groundbreaking inventions.

Conclusion

Shoichi Hazama's contributions to pharmaceutical technology through his innovative patents demonstrate his commitment to improving patient care. His work in predicting side effects and developing cancer treatments highlights the importance of genetic research in modern medicine.

Profile summary based on public USPTO records.